Your browser doesn't support javascript.
loading
Immunization with germ line-targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques.
Nelson, Ashley N; Shen, Xiaoying; Vekatayogi, Sravani; Zhang, Shiyu; Ozorowski, Gabriel; Dennis, Maria; Sewall, Leigh M; Milligan, Emma; Davis, Dominique; Cross, Kaitlyn A; Chen, Yue; van Schooten, Jelle; Eudailey, Joshua; Isaac, John; Memon, Saad; Weinbaum, Carolyn; Gao, Hongmei; Stanfield-Oakley, Sherry; Byrd, Alliyah; Chutkan, Suni; Berendam, Stella; Cronin, Kenneth; Yasmeen, Anila; Alam, S; LaBranche, Celia C; Rogers, Kenneth; Shirreff, Lisa; Cupo, Albert; Derking, Ronald; Villinger, Francois; Klasse, Per Johan; Ferrari, Guido; Williams, Wilton B; Hudgens, Michael G; Ward, Andrew B; Montefiori, David C; Van Rompay, Koen K A; Wiehe, Kevin; Moore, John P; Sanders, Rogier W; De Paris, Kristina; Permar, Sallie R.
  • Nelson AN; Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
  • Shen X; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Vekatayogi S; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Zhang S; Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA, USA.
  • Ozorowski G; Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA, USA.
  • Dennis M; Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
  • Sewall LM; Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA, USA.
  • Milligan E; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Davis D; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Cross KA; Gillings School of Public Health and Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Chen Y; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • van Schooten J; Department of Medical Microbiology, Academic Medical Center, Amsterdam, Netherlands.
  • Eudailey J; Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
  • Isaac J; Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
  • Memon S; Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
  • Weinbaum C; Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
  • Gao H; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Stanfield-Oakley S; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Byrd A; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Chutkan S; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Berendam S; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Cronin K; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Yasmeen A; Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA.
  • Alam S; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • LaBranche CC; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Rogers K; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA.
  • Shirreff L; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA.
  • Cupo A; Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA.
  • Derking R; Department of Medical Microbiology, Academic Medical Center, Amsterdam, Netherlands.
  • Villinger F; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, Netherlands.
  • Klasse PJ; New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA.
  • Ferrari G; Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA.
  • Williams WB; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Hudgens MG; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Ward AB; Gillings School of Public Health and Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Montefiori DC; Department of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA, USA.
  • Van Rompay KKA; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Wiehe K; California National Primate Research Center, University of California, Davis, CA, USA.
  • Moore JP; Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
  • Sanders RW; Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA.
  • De Paris K; Department of Medical Microbiology, Academic Medical Center, Amsterdam, Netherlands.
  • Permar SR; Department of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA.
Sci Immunol ; 9(98): eadm7097, 2024 Aug 30.
Article en En | MEDLINE | ID: mdl-39213340
ABSTRACT
Adolescents are a growing population of people living with HIV. The period between weaning and sexual debut presents a low-risk window for HIV acquisition, making early childhood an ideal time for implementing an immunization regimen. Because the elicitation of broadly neutralizing antibodies (bnAbs) is critical for an effective HIV vaccine, our goal was to assess the ability of a bnAb B cell lineage-designed HIV envelope SOSIP (protein stabilized by a disulfide bond between gp120-gp41-named "SOS"-and an isoleucine-to-proline point mutation-named "IP"-at residue 559) to induce precursor CD4 binding site (CD4bs)-targeting bnAbs in early life. Infant rhesus macaques received either a BG505 SOSIP, based on the infant BG505 transmitted/founder virus, or the CD4bs germ line-targeting BG505 SOSIP GT1.1 (n = 5 per group). Although both strategies induced durable, high-magnitude plasma autologous virus neutralization responses, only GT1.1-immunized infants (n = 3 of 5) exhibited VRC01-like CD4bs bnAb precursor development. Thus, a multidose immunization regimen with bnAb lineage-designed SOSIPs shows promise for inducing early B cell responses with the potential to mature into protective HIV bnAbs before sexual debut.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Vacunas contra el SIDA / Macaca mulatta Límite: Animals / Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Anti-VIH / Vacunas contra el SIDA / Macaca mulatta Límite: Animals / Humans Idioma: En Año: 2024 Tipo del documento: Article